Novocure (NSDQ:NVCR) today touted an analysis published in JAMA Oncology showing that its Optune-temozolomide combination helped newly-diagnosed glioblastoma patients live longer without hurting their quality of life.
In a Phase III pivotal trial, researchers found that a higher proportion of patients treated with Optune and temozolomide reported stable or improved quality of life measures compared to those treated with just temozolomide.
Get the full story at our sister site, Drug Delivery Business News.
The post Novocure touts quality-of-life analysis for glioblastoma patients treated with Optune-chemo combo appeared first on MassDevice.
from MassDevice http://ift.tt/2DVnvXZ
Cap comentari:
Publica un comentari a l'entrada